Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 9 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 6 | 2 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $115.29, accompanied by a high estimate of $140.00 and a low estimate of $84.00. This upward trend is evident, with the current average reflecting a 12.71% increase from the previous average price target of $102.29.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Gilead Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $130.00 | $123.00 |
| Tim Anderson | B of A Securities | Raises | Buy | $126.00 | $116.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $140.00 | $120.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $132.00 | $115.00 |
| James Shin | Deutsche Bank | Raises | Buy | $120.00 | $80.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $90.00 | $84.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $96.00 | $85.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $115.00 | $110.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $120.00 | $105.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $110.00 | $105.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $123.00 | $113.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $84.00 | $84.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $115.00 | $105.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $113.00 | $87.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gilead Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Gilead Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
A Deep Dive into Gilead Sciences's Financials
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 6.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 23.56%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 9.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.14%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.38, Gilead Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
